Researchers' Work from Kaiser Permanente Oakland Medical Center Focuses on Hearing Loss (A Biologic With Otologic Consequences: Analysis of Hearing Loss and Teprotumumab Using the Fda Adverse Event Reporting System).

A new report from researchers at Kaiser Permanente Oakland Medical Center in California examines the otologic adverse reactions (OARs), including hearing loss, associated with the use of teprotumumab, a biologic drug approved for the treatment of active thyroid eye disease. The researchers analyzed data from the Food and Drug Administration Adverse Events Reporting System (FAERS) and found that out of 2,109 cases involving teprotumumab, 14.05% reported OARs, with 7.06% reporting hearing loss specifically. Disproportionality analysis showed a significant association between teprotumumab and hearing loss. The study suggests that audiometric counseling and evaluation should be considered for patients receiving teprotumumab therapy, particularly older patients. [Extracted from the article]